CSL Limited Sponsored ADR (OTCMKTS:CSLLY) Sees Large Growth in Short Interest

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) saw a large growth in short interest in October. As of October 15th, there was short interest totaling 77,800 shares, a growth of 183.9% from the September 30th total of 27,400 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average trading volume of 292,200 shares, the short-interest ratio is presently 0.3 days. Based on an average trading volume of 292,200 shares, the short-interest ratio is presently 0.3 days. Currently, 0.0% of the company’s stock are sold short.

CSL Price Performance

Shares of CSLLY stock opened at $57.62 on Friday. The firm has a 50 day moving average price of $67.41 and a two-hundred day moving average price of $75.94. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.12 and a current ratio of 2.46. CSL has a 12-month low of $54.10 and a 12-month high of $96.79.

Analysts Set New Price Targets

CSLLY has been the subject of several analyst reports. Zacks Research upgraded CSL from a “strong sell” rating to a “hold” rating in a report on Monday, October 20th. Canaccord Genuity Group upgraded CSL from a “hold” rating to a “strong-buy” rating in a report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy”.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.